The case for & against
Bull & Bear analysis
Bullish
Linde plc (NYSE: LIN) is a leading global supplier of industrial gases and engineering solutions, serving diverse markets such as healthcare, food and beverage, electronics, chemicals, and energy. The company's strategic focus on low-carbon solutions and a strong project backlog enhances its competitive positioning in the rapidly evolving industrial gases market. Linde's operations are expansive, with a presence in over 100 countries, leveraging its infrastructure to deliver high-quality gases and technologies to its clients.
Bull says
- ↑Q1 FY26 EPS reached $4.33 (+10% YoY) with a 30% operating margin.
- ↑Project backlog of >$7B, including $1B+ for ultra-high-purity semiconductor plants.
- ↑Dividend increased 7% (33rd consecutive year) and $800M in share repurchases.
- ↑Analysts rate Strong Buy; $550 average price target implies upside.
- ↑Healthcare and electronics segments delivered resilient revenue growth.
- ↑Low leverage and positive interest-rate sensitivity support stability.
Bear says
- ↓Europe volumes remain sluggish due to persistent geopolitical tensions.
- ↓Helium prices down high-single digits, pressuring segment margins.
- ↓Negative earnings yield and weak growth indicators suggest profit risk.
- ↓Weak liquidity profile could strain operations in tighter capital markets.
- ↓Negative revisions and low balance-sheet strength signal health concerns.
- ↓Geopolitical uncertainty may cause contractual customers to cut gas volumes.
Investment themes with LIN
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-02-2026neutral
Transcript signals
Bull points
- The Lindy team delivered another solid quarter against a challenging economic backdrop. EPS of $4.33 grew 10%. Operating margins reached 30%. And return on capital remained at a healthy level of 24%. The high-quality compounding growth of our company, no matter what the environment, is a testament to the unwavering commitment of all 65,000 employees to create shareholder value.
- Sales of $8.8 billion were up 8% year-over-year, and net acquisitions contributed 1% from attractive roll-ups we've been executing globally.
- we signed nine more bolt-on acquisitions, primarily in the Americas, which will continue adding to future EPS growth.
Bear points
- And while we're experiencing those growth rates in most countries, the U.S. home care business has been relatively flat. In late 2025, a new U.S. health care policy resulted in less services for a specific piece of equipment, which is reflected in the current run rate and will continue for the next several quarters.
- It remains to be seen what the longer-term effects could be for the Middle East conflict, but so far, It appears activity is relocating to more feedstock-advantaged assets in Americas and, to a lesser extent, APAC.
- After that, we still anticipate excess molecules, allowing us to pursue new multi-year contracts with high quality customers. Therefore, I don't anticipate significant spot sales this year since we're focused on securing long-term agreements.
Read full transcript analysis ›